Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zana Brkic

Showing results (1-10 of 15) with videos related to

Pageof 2
Sort By:
Expert Review of Clinical Immunology|January 24, 2014
Type I IFN signature in primary Sjögren's syndrome patientsZana Brkic, Marjan A Versnel
Frontiers in Immunology|June 29, 2026
Type I interferon pathway activation in connective tissue disease associated interstitial lung diseaseTobias M Defesche, Thomas Koudstaal, Marjan A Versnel, et al.
Rheumatology (Oxford, England)|October 31, 2014
Prevalence of distal renal tubular acidosis in primary Sjögren's syndromeTim Both, Ewout J Hoorn, Robert Zietse, et al.
Annals of the Rheumatic Diseases|June 28, 2012
Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expressionZana Brkic, Naomi I Maria, Cornelia G van Helden-Meeuwsen, et al.
Annals of the Rheumatic Diseases|July 9, 2013
MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndromeNaomi I Maria, Zana Brkic, Matti Waris, et al.
RMD Open|May 9, 2025
Amlexanox inhibits production of type I interferon and suppresses B cell differentiation <i>in vitro</i>: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseasesAlbin Björk, Mohamed Javad Wahadat, Maria Sánchez-Blázquez, et al.
Rheumatology (Oxford, England)|September 10, 2021
Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndromeErika Huijser, Jens Göpfert, Zana Brkic, et al.
Frontiers in Oncology|April 10, 2023
Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren's syndrome patients through immunogeneticsP Martijn Kolijn, Erika Huijser, M Javad Wahadat, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndromeNaomi I Maria, Eline C Steenwijk, Arne S IJpma, et al.
Journal of Translational Autoimmunity|February 3, 2021
Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology departmentNiels A D Guchelaar, Jan A M van Laar, Maud A W Hermans, et al.
Pageof 2

Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Expert Review of Clinical Immunology|January 24, 2014
Type I IFN signature in primary Sjögren's syndrome patientsZana Brkic, Marjan A Versnel
Frontiers in Immunology|June 29, 2026
Type I interferon pathway activation in connective tissue disease associated interstitial lung diseaseTobias M Defesche, Thomas Koudstaal, Marjan A Versnel, et al.
Rheumatology (Oxford, England)|October 31, 2014
Prevalence of distal renal tubular acidosis in primary Sjögren's syndromeTim Both, Ewout J Hoorn, Robert Zietse, et al.
Annals of the Rheumatic Diseases|June 28, 2012
Prevalence of interferon type I signature in CD14 monocytes of patients with Sjogren's syndrome and association with disease activity and BAFF gene expressionZana Brkic, Naomi I Maria, Cornelia G van Helden-Meeuwsen, et al.
Annals of the Rheumatic Diseases|July 9, 2013
MxA as a clinically applicable biomarker for identifying systemic interferon type I in primary Sjogren's syndromeNaomi I Maria, Zana Brkic, Matti Waris, et al.
RMD Open|May 9, 2025
Amlexanox inhibits production of type I interferon and suppresses B cell differentiation <i>in vitro</i>: a possible therapeutic option for systemic lupus erythematosus and other systemic inflammatory diseasesAlbin Björk, Mohamed Javad Wahadat, Maria Sánchez-Blázquez, et al.
Rheumatology (Oxford, England)|September 10, 2021
Serum interferon-α2 measured by single-molecule array associates with systemic disease manifestations in Sjögren's syndromeErika Huijser, Jens Göpfert, Zana Brkic, et al.
Frontiers in Oncology|April 10, 2023
Extranodal marginal zone lymphoma clonotypes are detectable prior to eMZL diagnosis in tissue biopsies and peripheral blood of Sjögren's syndrome patients through immunogeneticsP Martijn Kolijn, Erika Huijser, M Javad Wahadat, et al.
Annals of the Rheumatic Diseases|September 28, 2016
Contrasting expression pattern of RNA-sensing receptors TLR7, RIG-I and MDA5 in interferon-positive and interferon-negative patients with primary Sjögren's syndromeNaomi I Maria, Eline C Steenwijk, Arne S IJpma, et al.
Journal of Translational Autoimmunity|February 3, 2021
Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology departmentNiels A D Guchelaar, Jan A M van Laar, Maud A W Hermans, et al.
Pageof 2